Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector14110.17816/psaic141Original articlesОригинальные статьиUnknownBiomarkers of cerebral atherosclerosis: the capabilities of early diagnosis and prognosis of individual riskБиомаркеры церебрального атеросклероза: возможности ранней диагностики и прогнозирования индивидуального рискаhttps://orcid.org/0000-0002-5883-8119TanashyanMarine M.ТанашянМаринэ Мовсесовна
Russian Federation

D. Sci. (Med.), Prof., Corresponding member of RAS, Deputy Director for science, Head, 1st Neurological department

д.м.н., профессор, член-корреспондент РАН, зам. директора по научной работе, рук. 1-го неврологического отделения

rasckey@live.comhttps://orcid.org/0000-0003-0522-767XRaskurazhevAnton A.РаскуражевАнтон Алексеевич
Russian Federation

Cand. Sci. (Med.), neurologist, researcher, 1st Neurology department

к.м.н., врач-невролог, с.н.с. 1-го неврологического отделения

rasckey@live.comhttps://orcid.org/0000-0001-9604-7775ShabalinaAlla A.ШабалинаАлла Анатольевна
Russian Federation

D. Sci. (Med.), leading researcher, Head, Laboratory of hemorheology, hemostasis and pharmacokinetics (with clinical laboratory diagnostics)

д.м.н., в.н.с., рук. лаб. гемореологии, гемостаза и фармакокинетики (с клинической лабораторной диагностикой)

rasckey@live.comLagodaOlga V.ЛагодаОльга Викторовна
Russian Federation
rasckey@live.comGnedovskayaElena V.ГнедовскаяЕлена Владимировна
Russian Federation
rasckey@live.comResearch Center of NeurologyФГБНУ «Научный центр неврологии»0909201593202501022017Copyright ©; 2015, Tanashyan M.M., Raskurazhev A.A., Shabalina A.A., Lagoda O.V., Gnedovskaya E.V.Copyright ©; 2015, Tanashyan M.M., Raskurazhev A.A., Shabalina A.A., Lagoda O.V., Gnedovskaya E.V.2015Tanashyan M.M., Raskurazhev A.A., Shabalina A.A., Lagoda O.V., Gnedovskaya E.V.Tanashyan M.M., Raskurazhev A.A., Shabalina A.A., Lagoda O.V., Gnedovskaya E.V.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/141

The article discusses the results of a study of asymptomatic patients with a severe stenosing process in the brachiocephalic arteries (in a model of carotid atherosclerosis), with emphasis on determination of biochemical markers associated with various stages of atherogenesis. The definition of a group of proatherogenic and atheroprotective biomarkers is suggested and substantiated. Correlations among biomarkers are described. The correlations have potential etiopathogenetic nature, which necessitates further validation of these pathological changes in wider groups of patients.

В статье обсуждаются результаты исследования группы «асимптомных» пациентов с выраженной степенью стенозирующего процесса в брахио-цефальных артериях (на модели каротидного атеросклероза) с акцентом на определение биохимических маркеров, отражающих различные звенья атерогенеза. Предлагается и обосновывается выделение группы проатерогенных и атеропротективных биомаркеров. Описываются корреляции между биомаркерами, носящие потенциально этиопатогенетический характер, что обусловливает необходимость дальнейшей валидации указанных патологических изменений на более широких группах пациентов.

atherosclerosis of brachiocephalic arteriesasymptomatic stenosesbiomarkersendothelial dysfunctionhemorheology and hemostasisатеросклероз брахиоцефальных артерий«асимптомные» стенозыбиомаркерыэндотелиальная дисфункциягемореология и гемостазОрлов С.В., Домашенко М.А., Костырева М.В. и др. Гемореология и гемостаз у больных с ишемическими инсультами на фоне метаболического синдрома. Клиническая медицина 2007; 85 (1): 40–43.Суслина З.А., Танашян М.М., Лагода О.В. Атеросклероз и ишемические нарушения мозгового кровообращения. Атеротромбоз 2009; 2: 60–67.Танашян М.М. Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии. Анн. клинич. и эксперим. неврологии 2007; 1 (2): 29–33.Танашян М.М., Лагода О.В., Гулевская Т.С. и др. Прогрессирующий церебральный атеросклероз: клинические, биохимические и морфологические аспекты. Анн. клинич. и эксперим. неврологии 2013; 7 (4): 4–9.Abbasi F., Asagmi T., Cooke J.P. et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201–1203.Alessi M.C., Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006 Oct; 26 (10): 2200–2207.Arita Y., Kihara S., Ouchi N. et al. Adipocytederived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105: 2893–2898.Aronson J.K. Biomarkers and surrogate endpoints. Br J Clin Pharmacol. 2005; 59: 5; 491–494.Ballantyne C.M., Hoogeveen R.C., Bang H. et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2005; 165: 2479–2484.Bergh N., Ulfhammer E., Glise K. et al. Influence of TNF-α and biomechanical stress on endothelial anti- and prothrombotic genes. Biochem Biophys Res Commun 2009; 385: 314–318.Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.Boger R.H., Bode-Boger S.M., Szuba A. et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.Bouch J.L., Hansen H., Feener E.P. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998; 18: 1771–1779.Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421–1428.Hotta K., Funahashi T., Arita Y. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20: 1595–1599.Iglseder B., Mackevics V., Stadlmayer A. et al. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005 Dec; 36 (12):2577–2582.Kleinbongard Р., Heusch G., Schulz R. TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacology &Therapeutics 127; 2010; 295–314.Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23: 85–89.Legator MS, Morris DL. What did Sir Bradford Hill really say? Arch Environ Health 2003; 58: 718–720.Levi, M., Keller, T. T., van, G. E., & Ten, C. H. (2003). Infection and inflammation and the coagulation system. Cardiovasc Res 60, 26–39.Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. Transatlantic Network on Atherothrombosis. J Am Coll Cardiol. 2009 Dec 1; 54 (23): 2129–2138.Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001; 88: 756–762.Miyazaki H., Matsuoka H., Cooke J.P. et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99: 1141–1146.Okamoto Y., Arita Y., Nishida M. et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000; 32: 47–50.Okamoto Y., Kihara S., Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002; 106: 2767–2770.Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100: 2473–2476.Ouchi N, Kihara S, Arita Y et al. Adipocytederived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103: 1057–1063.Ouchi N., Kihara S., Arita Y. et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296–1301.Pandolfi A., Cetrullo D., Polishuck R. et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 2001 Aug; 21 (8): 1378–1382.Paone J.F., Waalkes T.P., Baker R.R., Shaper J.H. Serum UDPgalactosyl transferase as a potential biomarker for breast carcinoma. J Surg Oncol 1980; 15: 59–66.Searle J., Danne O., Müller C., Mockel M. Biomarkers in acute coronary syndrome and percutaneous coronary intervention. Minerva Cardioangiol. 2011 Jun; 59 (3): 203–223.Vaughan D.E. “PAI-1 and atherothrombosis,” Journal of Thrombosis and Haemostasis 2005; 3 (8): 1879–1883.Yoon J.-H., Kim S.-K., Choi H.-J. et al. Adiponectin Provides Additional Information to Conventional Cardiovascular Risk Factors for Assessing the Risk of Atherosclerosis in Both Genders. 2013. PLoS ONE 8 (10): e75535. doi:10.1371/journal.pone.0075535.